Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia

Geoffrey L. Uy, Sarit Assouline, Anne Marie Young, Steven Blotner, Brian Higgins, Lin Chi Chen, Karen Yee

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

In acute myeloid leukemia (AML), TP53 mutations and dysregulation of wild-type p53 is common and supports an MDM2 antagonist as a therapy. RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin (active principle [AP]) that allows for IV administration. This phase 1 monotherapy study evaluated the safety, pharmacokinetics, and pharmacodynamics of RO6839921 in patients with AML. Primary objectives identified dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD). Secondary objectives assessed pharmacokinetic, pharmacodynamic, and antileukemic activity. A total of 26 patients received 120–300 mg AP of idasanutlin. The MTD was 200 mg, with DLTs at 250 (2/8 patients) and 300 mg (2/5). Treatment–related adverse events in '20% of patients were diarrhea, nausea, vomiting, decreased appetite, and fatigue. Six deaths (23.1%) occurred, all unrelated to treatment. Pharmacokinetics showed rapid and near-complete conversion of the prodrug to AP and dose-proportional exposure across doses. Variability ranged from 30%–47% (22%–54% for idasanutlin). TP53 was 21 (87.5%) wild-type and 3 mutant (12.5%). The composite response rate (complete remission [CR], CR with incomplete hematologic recovery/morphological leukemia-free state [CRi/MLFS], or CR without platelet recovery [CRp]) was 7.7%. Antileukemic activity (CR, CRi/MLFS, partial response, hematologic improvement/stable disease) was observed in 11 patients (disease control rate, 42%): 10/11 were TP53 wild-type; 1 had no sample. p53 activation was demonstrated by MIC-1 induction and was associated with AP exposure. There was not sufficient differentiation or improvement in the biologic or safety profile compared with oral idasanutlin to support continued development of RO6839921. NCT02098967.

Original languageEnglish
Pages (from-to)1430-1441
Number of pages12
JournalInvestigational New Drugs
Volume38
Issue number5
DOIs
StatePublished - Oct 1 2020

Keywords

  • Acute myeloid leukemia
  • Idasanutlin
  • MDM2
  • Safety

Fingerprint

Dive into the research topics of 'Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this